{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-021758","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.483377+00:00","generated_at":"2026-06-24T02:04:59.881195+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid Therapeutics Q2 2022 net loss $14.6M; cash $152.4M; OV329 IND on track for H2 2022","bullets":["Net loss $14.6M ($0.21 per share) vs $15.8M loss ($0.23) in Q2 2021.","Cash, equivalents & marketable securities $152.4M, expected to fund pipeline into 2025.","R&D expenses $6.0M (down from $7.7M) due to discontinuation of OV101 study and Takeda termination.","OV329 IND submission and Phase 1 start planned for H2 2022; preclinical data shown at epilepsy meetings.","KCC2 activator IND expected in 2024; Takeda reiterates soticlestat regulatory filing in FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-021758","json":"https://secwatch.observer/filing/0001628280-22-021758.json","markdown":"https://secwatch.observer/filing/0001628280-22-021758.md","text":"https://secwatch.observer/filing/0001628280-22-021758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828022021758/0001628280-22-021758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828022021758/ovid-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:04:59.881195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}